Advancements in Aggressive Non-Hodgkin Lymphoma Trials

This chapter focuses on the evolving landscape of clinical trials for aggressive non-Hodgkin lymphoma, particularly in high-risk patient subsets. It emphasizes the role of circulating tumor DNA in monitoring treatment responses and redefining remission assessments to improve patient management and outcomes.